Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 2, Issue 7, pp. 643-654
PubMed
Published By
Print ISSN
Online ISSN
History
- Received December 4, 2013
- Revision received April 4, 2014
- Accepted April 21, 2014
- Published first April 29, 2014.
Article Versions
- Previous version (April 29, 2014 - 06:35).
- Previous version (June 5, 2014 - 06:59).
- You are viewing the most recent version of this article.
Copyright & Usage
©2014 American Association for Cancer Research.
Author Information
- Zachary A. Cooper1,2,
- Vikram R. Juneja3,4,5,
- Peter T. Sage4,5,
- Dennie T. Frederick6,
- Adriano Piris5,7,
- Devarati Mitra5,
- Jennifer A. Lo5,
- F. Stephen Hodi5,9,
- Gordon J. Freeman5,9,
- Marcus W. Bosenberg11,
- Martin McMahon12,13,
- Keith T. Flaherty5,6,
- David E. Fisher5,8,
- Arlene H. Sharpe4,5,10, and
- Jennifer A. Wargo1,2,*
- Authors' Affiliations: Departments of 1Surgical Oncology and
- 2Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas;
- 3Harvard-MIT Division of Health Sciences and Technology, Cambridge;
- 4Department of Microbiology and Immunobiology;
- 5Harvard Medical School; Divisions of
- 6Medical Oncology,
- 7Dermatopathology, and
- 8Dermatology, Massachusetts General Hospital;
- 9Department of Medical Oncology, Dana-Farber Cancer Institute;
- 10Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts;
- 11Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut;
- 12Helen Diller Family Comprehensive Cancer Center; and
- 13Department of Cell and Molecular Pharmacology, University of California San Francisco, San Francisco, California
- ↵*Corresponding Author:
Jennifer A. Wargo, University of Texas MD Anderson Cancer Center, Surgical Oncology, 1515 Holcombe Boulevard SCT17.6010, Houston, TX 77030. Phone: 713-745-1553; Fax: 713-745-2436; E-mail: jwargo{at}mdanderson.org
Z.A. Cooper, V.R. Juneja, P.T. Sage, A.H. Sharpe, and J.A. Wargo contributed equally to this work.
July 2014
Volume 2, Issue 7
Volume 2, Issue 7
Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
Jump to section
Advertisement